Processa Pharmaceuticals, Inc. (PCSA) Financials

PCSA Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 4.5 million 2.0 million
Dec. 31, 2025 7.8 million 2.2 million
Sept. 30, 2025 7.6 million 1.8 million
June 30, 2025 8.2 million 2.1 million

PCSA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.6 million 95963
Dec. 31, 2025 -2.9 million 351252
Sept. 30, 2025 -3.5 million 75336
June 30, 2025 -2.3 million 430962

PCSA Net Income

No data available :(

PCSA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.7 million - -
Dec. 31, 2025 5.5 million - -
Sept. 30, 2025 6.3 million - -
June 30, 2025 6.9 million - 25584

PCSA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 2.6 million
Dec. 31, 2025 2.6 million
Sept. 30, 2025 1.9 million
June 30, 2025 622772

PCSA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 1.8 million 1.5 million -301
Dec. 31, 2025 2 2.1 million 1.6 million -
Sept. 30, 2025 - 1.7 million 1.8 million -
June 30, 2025 - 2.4 million 1.5 million -

PCSA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 301
Dec. 31, 2025 - 301
Sept. 30, 2025 - 301
June 30, 2025 - 301

PCSA

Price: $2.12

52 week price:
1.76
19.63

Earnings Per Share: -4.07 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 125600

Market Capitalization: 6.3 million

Links: